Senate Hearing on Coronavirus Crisis Exposes Dangers of US Dependence on China for Drug Sourcing

Senate Hearing on Coronavirus Crisis Exposes Dangers of US Dependence on China for Drug Sourcing
Senate Judiciary Committee member Sen. Josh Hawley (R-Mo.) at the Capitol in Washington on Jan. 15, 2019. (Charlotte Cuthbertson/The Epoch Times)
Mark Tapscott

WASHINGTON—Millions of Americans depend on drugs that are made in part or wholly in China because U.S. manufacturers moved their supply chains and much of their manufacturing facilities to that country, the Senate Committee on Small Business and Entrepreneurship was told on March 12.

“Thousands of our generic drugs and even some of the brand name products and perhaps even new therapies for coronavirus may depend on the chemicals that are sourced primarily in China,” Rosemary Gibson, a senior adviser to the Garrison, New York-based Hastings Center Bioethics Research Institute, told the committee.

The hearing’s focus was on “Coronavirus and America’s small business supply chain.”

Gibson was responding to Sen. Josh Hawley (R-Mo.), who had asked, “How many of our drugs involve Chinese production—maybe they’re not made wholly there, but Chinese production is involved?”

Gibson said, “If you are hospitalized with coronavirus, if you have a severe case, which thankfully are small numbers, you might need a ventilator. You will need sedatives like fentanyl and propofol.

“Your blood pressure may get dangerously low, so you will need pressers like dopamine and epinephrine. You might get a secondary infection that is bacterial in nature, and you will need antibiotics. You might become septic, which is life-threatening.”

Gibson told the committee that she was recently “sitting in a room with the people that actually make medicines. These are the men and women in pharmaceutical engineering and pharmaceutical chemistry.”

“I said, ‘So tell me, if you have to make these tomorrow, where do the core chemicals come from to make it? How much are we dependent on China?’ They said 90 percent of the chemicals to make those basic generic drugs depend on China.”

Earlier this month, after the U.S. restricted travel to and from China, Xinhua, China’s state-controlled official news agency, said that “these practices in the United States [restricting travel from China to the United States] are very unkind. They can be described as falling into the ground and killing people while they are ill.”

The Chinese news agency then added ominously, “If China retaliates against the U.S. at this time, in addition to announcing a travel ban on the United States, it will also announce strategic control over medical products and ban exports to the United States.”

Politico reported in December that “last year, China accounted for 95 percent of U.S. imports of ibuprofen, 91 percent of U.S. imports of hydrocortisone, 70 percent of U.S. imports of acetaminophen, 40 to 45 percent of U.S. imports of penicillin and 40 percent of U.S. imports of heparin, according to Commerce Department data. In all, 80 percent of the U.S. supply of antibiotics are made in China.”

Gibson said the situation isn’t totally hopeless, however, because “the good news is there is advanced manufacturing technology and really brilliant chemists right here in the United States that want to make it capable of starting production tomorrow.”

In her prepared testimony, Gibson described the national security risks involved in U.S. dependence on Chinese drug production if Beijing follows through on the threat published by Xinhua.

“The unleashing of this threat will cause unprecedented deaths and social disorder on a scale never seen before on our country. The civilian and military health care systems will collapse. China can wreak other havoc. Medicines in the hands of an adversary can be weaponized,” Gibson testified.

“Medicines can be made with lethal contaminants or sold without any real medicine in them, rendering them ineffective. These products can be distributed to specific targets. Detection is time-consuming at best, and virtually impossible at worst.

“Dependence on China is a risk to the U.S. military, combat readiness, and force protection. The thousands of men and women on U.S. aircraft carriers in the South China Sea are dependent on the adversary for many of their essential medicines.

“Combat readiness and force protection are at risk with the military vulnerable to disruptions in supply and contaminated and toxic medicines. In 2018, more than 31,000 active-duty military personnel, veterans, and their family members were notified they may have been given blood pressure medicines containing a cancer-causing ingredient.”

Another witness, Dr. Tim Morrison, a senior fellow at the Hudson Institute, said China’s “Made in China 2025” initiative signals Beijing’s long-term goal of moving from being a manufacturing power to producing higher-value products and services such as prescription drugs and related medical products.

“I think the point of Made in China 2025 is essentially to destroy the free market and create incentives to offshore production in China,“ he said. ”And, originally, this seemed like a good thing. We‘ll save prices. We’ll move value, or value you can move, we’ll continue to do the innovation, but China is scooping that up as well. And so, without any decision by any government authority, this happened, and now we are going to deal with the consequences.”

Hawley concluded his questioning by noting that “our current drug policy seems to privilege economic considerations of maybe a few companies over public health considerations.”

Morrison said he agreed with Hawley’s characterization.

Contact Mark Tapscott at [email protected]
Mark Tapscott is an award-winning investigative editor and reporter who covers Congress, national politics, and policy for The Epoch Times. Mark was admitted to the National Freedom of Information Act (FOIA) Hall of Fame in 2006 and he was named Journalist of the Year by CPAC in 2008. He was a consulting editor on the Colorado Springs Gazette’s Pulitzer Prize-winning series “Other Than Honorable” in 2014.
Related Topics